{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T13:53:23Z","timestamp":1772632403861,"version":"3.50.1"},"reference-count":46,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>This review aims to summarize how scientific advances in complement biology have not only improved the diagnosis and management of aHUS but also continue to offer insights into the pathophysiology of complement-mediated disease that may be leveraged for future therapeutic developments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>Updated information on the clinical and epidemiological features, pathophysiology, diagnosis, management, and potential for future therapeutic advancements in the treatment of aHUS are reviewed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>aHUS is a rare but potentially life-threatening disease that requires prompt diagnosis and treatment as well as long-term management via a multidisciplinary team providing coordination of primary and specialty care as well as outreach and education for children and families affected by this life-long disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/mop.0000000000001435","type":"journal-article","created":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T07:00:46Z","timestamp":1738220446000},"page":"219-225","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Updates in atypical hemolytic syndrome"],"prefix":"10.1097","volume":"38","author":[{"given":"Keri","family":"Drake","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jyothsna","family":"Gattineni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2026,3,5]]},"reference":[{"key":"R1-20260304","first-page":"905","article-title":"[Hemolytic-uremic syndrome: bilateral necrosis of the renal cortex in acute acquired hemolytic anemia]","volume":"85","author":"Gasser","year":"1955","journal-title":"Schweiz Med Wochenschr"},{"key":"R2-20260304","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.kint.2024.05.021","article-title":"An expert discussion on the atypical hemolytic uremic syndrome nomenclature-identifying a road map to precision: a report of a National Kidney Foundation Working Group","volume":"106","author":"Nester","year":"2024","journal-title":"Kidney Int"},{"key":"R3-20260304","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1016\/S0140-6736(22)01202-8","article-title":"Haemolytic uraemic syndrome","volume":"400","author":"Michael","year":"2022","journal-title":"Lancet"},{"key":"R4-20260304","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.nefro.2015.07.005","article-title":"An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. a consensus document","volume":"35","author":"Campistol","year":"2015","journal-title":"Nefrologia"},{"key":"R5-20260304","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00467-015-3076-8","article-title":"An international consensus approach to the management of atypical hemolytic uremic syndrome in children","volume":"31","author":"Loirat","year":"2016","journal-title":"Pediatr Nephrol"},{"key":"R6-20260304","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1053\/j.ajkd.2004.02.010","article-title":"Nonenteropathic hemolytic uremic syndrome: causes and short-term course","volume":"43","author":"Constantinescu","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"R7-20260304","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2147\/CLEP.S245642","article-title":"Epidemiology of atypical hemolytic uremic syndrome: a systematic literature review","volume":"12","author":"Yan","year":"2020","journal-title":"Clin Epidemiol"},{"key":"R8-20260304","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.4049\/jimmunol.176.3.1305","article-title":"The central role of the alternative complement pathway in human disease","volume":"176","author":"Thurman","year":"2006","journal-title":"J Immunol"},{"key":"R9-20260304","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1056\/NEJM200104053441406","article-title":"Complement. First of two parts","volume":"344","author":"Walport","year":"2001","journal-title":"N Engl J Med"},{"key":"R10-20260304","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/1750-1172-6-60","article-title":"Atypical hemolytic uremic syndrome","volume":"6","author":"Loirat","year":"2011","journal-title":"Orphanet J Rare Dis"},{"key":"R11-20260304","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1681\/ASN.2010030315","article-title":"Clinical features of antifactor H autoantibody-associated hemolytic uremic syndrome","volume":"21","author":"Dragon-Durey","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"R12-20260304","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1007\/s00467-018-4039-7","article-title":"Extra-renal manifestations of atypical hemolytic uremic syndrome","volume":"34","author":"Formeck","year":"2019","journal-title":"Pediatr Nephrol"},{"key":"R13-20260304","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1007\/s00467-018-3933-3","article-title":"Extra-renal manifestations of atypical hemolytic uremic syndrome in children","volume":"33","author":"Fidan","year":"2018","journal-title":"Pediatr Nephrol"},{"key":"R14-20260304","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/nrneph.2013.280","article-title":"Cardiovascular complications in atypical haemolytic uraemic syndrome","volume":"10","author":"Noris","year":"2014","journal-title":"Nat Rev Nephrol"},{"key":"R15-20260304","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1007\/s00467-014-2817-4","article-title":"An audit analysis of a guideline for the investigation and initial therapy of diarrhea negative (atypical) hemolytic uremic syndrome","volume":"29","author":"Johnson","year":"2014","journal-title":"Pediatr Nephrol"},{"key":"R16-20260304","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1681\/ASN.2006080811","article-title":"Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome","volume":"18","author":"Sellier-Leclerc","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"R17-20260304","doi-asserted-by":"crossref","first-page":"e62","DOI":"10.3928\/01913913-20140923-03","article-title":"Recurrent ocular involvement in pediatric atypical hemolytic uremic syndrome","volume":"51","author":"Zheng","year":"2014","journal-title":"J Pediatr Ophthalmol Strabismus"},{"key":"R18-20260304","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1007\/s00467-007-0540-0","article-title":"Ocular involvement in hemolytic uremic syndrome due to factor H deficiency--are there therapeutic consequences?","volume":"22","author":"Larakeb","year":"2007","journal-title":"Pediatr Nephrol"},{"key":"R19-20260304","doi-asserted-by":"crossref","first-page":"841051","DOI":"10.3389\/fped.2022.841051","article-title":"Case report: atypical HUS presenting with acute rhabdomyolysis highlights the need for individualized eculizumab dosing","volume":"10","author":"Benoit","year":"2022","journal-title":"Front Pediatr"},{"key":"R20-20260304","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.semnephrol.2013.08.003","article-title":"Atypical hemolytic uremic syndrome","volume":"33","author":"Kavanagh","year":"2013","journal-title":"Semin Nephrol"},{"key":"R21-20260304","doi-asserted-by":"crossref","first-page":"E1445","DOI":"10.1002\/humu.21256","article-title":"Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome","volume":"31","author":"Maga","year":"2010","journal-title":"Hum Mutat"},{"key":"R22-20260304","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.pcl.2022.07.006","article-title":"Hemolytic-uremic syndrome in children","volume":"69","author":"Boyer","year":"2022","journal-title":"Pediatr Clin North Am"},{"key":"R23-20260304","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/ki.2009.472","article-title":"Mutations in components of complement influence the outcome of factor I-associated atypical hemolytic uremic syndrome","volume":"77","author":"Bienaime","year":"2010","journal-title":"Kidney Int"},{"key":"R24-20260304","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.molimm.2007.05.004","article-title":"Characterization of mutations in complement factor I (CFI) associated with hemolytic uremic syndrome","volume":"45","author":"Kavanagh","year":"2008","journal-title":"Mol Immunol"},{"key":"R25-20260304","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s00467-020-04714-0","article-title":"Different approaches to long-term treatment of aHUS due to MCP mutations: a multicenter analysis","volume":"36","author":"Klambt","year":"2021","journal-title":"Pediatr Nephrol"},{"key":"R26-20260304","doi-asserted-by":"crossref","first-page":"607211","DOI":"10.3389\/fimmu.2020.607211","article-title":"Factor H autoantibodies and complement-mediated diseases","volume":"11","author":"Zhang","year":"2020","journal-title":"Front Immunol"},{"key":"R27-20260304","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.molimm.2022.08.011","article-title":"Overview on the role of complement-specific autoantibodies in diseases","volume":"151","author":"Matola","year":"2022","journal-title":"Mol Immunol"},{"key":"R28-20260304","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1007\/s00467-022-05862-1","article-title":"Variants in complement genes are uncommon in patients with antifactor H autoantibody-associated atypical hemolytic uremic syndrome","volume":"38","author":"Khandelwal","year":"2023","journal-title":"Pediatr Nephrol"},{"key":"R29-20260304","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.kint.2018.02.029","article-title":"Clinical and genetic predictors of atypical hemolytic uremic syndrome phenotype and outcome","volume":"94","author":"Schaefer","year":"2018","journal-title":"Kidney Int"},{"key":"R30-20260304","doi-asserted-by":"crossref","first-page":"931210","DOI":"10.3389\/fimmu.2022.931210","article-title":"Antifactor H antibody and its role in atypical hemolytic uremic syndrome","volume":"13","author":"Raina","year":"2022","journal-title":"Front Immunol"},{"key":"R31-20260304","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1007\/s00467-024-06284-x","article-title":"Antifactor B antibodies in atypical hemolytic uremic syndrome","volume":"39","author":"Khandelwal","year":"2024","journal-title":"Pediatr Nephrol"},{"key":"R32-20260304","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.imlet.2014.01.014","article-title":"Autoantibodies to complement components in C3 glomerulopathy and atypical hemolytic uremic syndrome","volume":"160","author":"J\u00f3zsi","year":"2014","journal-title":"Immunol Lett"},{"key":"R33-20260304","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.2215\/CJN.02730409","article-title":"Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome","volume":"4","author":"Thurman","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"R34-20260304","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/nbt1344","article-title":"Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria","volume":"25","author":"Rother","year":"2007","journal-title":"Nat Biotechnol"},{"key":"R35-20260304","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2015.12.034","article-title":"Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-arm, open-label trial","volume":"68","author":"Fakhouri","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"R36-20260304","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.kint.2015.11.026","article-title":"Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome","volume":"89","author":"Greenbaum","year":"2016","journal-title":"Kidney Int"},{"key":"R37-20260304","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/ki.2014.423","article-title":"Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies","volume":"87","author":"Licht","year":"2015","journal-title":"Kidney Int"},{"key":"R38-20260304","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s12882-019-1314-1","article-title":"Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study","volume":"20","author":"Menne","year":"2019","journal-title":"BMC Nephrol"},{"key":"R39-20260304","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s00467-017-3813-2","article-title":"Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome: an update","volume":"33","author":"Ardissino","year":"2018","journal-title":"Pediatr Nephrol"},{"key":"R40-20260304","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1080\/19420862.2015.1086049","article-title":"Therapeutic drug monitoring of eculizumab: rationale for an individualized dosing schedule","volume":"7","author":"Gatault","year":"2015","journal-title":"MAbs"},{"key":"R41-20260304","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s00467-020-04774-2","article-title":"The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab","volume":"36","author":"Tanaka","year":"2021","journal-title":"Pediatr Nephrol"},{"key":"R42-20260304","doi-asserted-by":"crossref","first-page":"104134","DOI":"10.1016\/j.drudis.2024.104134","article-title":"The efficacy and safety of eculizumab in patients and the role of C5 polymorphisms","volume":"29","author":"Bouwman","year":"2024","journal-title":"Drug Discov Today"},{"key":"R43-20260304","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1007\/s00467-024-06374-w","article-title":"Managing antifactor H antibody-associated hemolytic uremic syndrome: time for consensus","volume":"39","author":"Khandelwal","year":"2024","journal-title":"Pediatr Nephrol"},{"key":"R44-20260304","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1681\/ASN.2017070738","article-title":"The MFHR1 fusion protein is a novel synthetic multitarget complement inhibitor with therapeutic potential","volume":"29","author":"Michelfelder","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"R45-20260304","doi-asserted-by":"crossref","first-page":"3580","DOI":"10.3390\/cells10123580","article-title":"Pediatric atypical hemolytic uremic syndrome advances","volume":"10","author":"Raina","year":"2021","journal-title":"Cells"},{"key":"R46-20260304","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1007\/s00467-023-06158-8","article-title":"Voice of a caregiver: call for action for multidisciplinary teams in the care for children with atypical hemolytic uremic syndrome","volume":"39","author":"Burke","year":"2024","journal-title":"Pediatr Nephrol"}],"container-title":["Current Opinion in Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MOP.0000000000001435","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T07:00:53Z","timestamp":1772607653000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MOP.0000000000001435"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,5]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/mop.0000000000001435","relation":{},"ISSN":["1531-698X"],"issn-type":[{"value":"1531-698X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,5]]}}}